FDA sets June date for latest review of Merck’s last-ditch antibioticThe FDA has started a six-month priority review of Merck & Co/MSD’s triple antibiotic Recarbrio in a new Share XFDA sets June date for latest review of Merck’s last-ditch antibiotichttps://pharmaphorum.com/news/fda-sets-june-date-for-latest-review-of-mercks-last-ditch-antibiotic/
Merck’s last-resort antibiotic Recarbrio nears EU approvalMerck & Co/MSD’s three-drug antibiotic Recarbrio has been recommended for approval in Europe for Gram-negative infections, but should Share XMerck’s last-resort antibiotic Recarbrio nears EU approvalhttps://pharmaphorum.com/news/mercks-last-resort-antibiotic-recarbrio-nears-eu-approval/
